TABLE 1. Patients' baseline characteristics* (bDAMRDs: biologic disease-modifying antirheumatic drugs, SD: standard deviation)

	New users of		**Switchers to**	
	Tofacitinib (n = 1,031)	**bDMARDs (n = 17,803)**	**Tofacitinib (n = 1,535)**	**bDMARDs (n = 9,849)**
Duration of available follow-up in years† mean (SD)	1.70 (0.98)	1.73 (1.08)	1.74 (1.07)	1.74 (1.1)
Demographics				
Females	844 (81.9)	13,925 (78.2)	1,278 (83.3)	8,001 (81.2)
Age – mean (SD)	56.4 (11.3)	52.9 (12.0)	53.9 (11.1)	52.9 (11.6)
Socioeconomic status				
Low	192 (18.6)	3,279 (18.4)	275 (17.9)	1,844 (18.7)
2nd quarter	158 (15.3)	3,196 (18.0)	313 (20.4)	1,932 (19.6)
3rd quarter	197 (19.1)	3,284 (18.5)	284 (18.5)	1,780 (18.1)
High	188 (18.2)	3,289 (18.5)	285 (18.6)	1,834 (18.6)
Unknown	296 (28.7)	4,755 (26.7)	378 (24.6)	2,459 (25.0)
Relation to Employee				

	New users of		Switchers to	
	Tofacitinib (n = 1,031)	**bDMARDs (n = 17,803)**	**Tofacitinib (n = 1,535)**	**bDMARDs (n = 9,849)**
Employee	622 (60.3)	11,245 (63.2)	859 (56)	6,044 (61.4)
Spouse/dependent	409 (39.7)	6,558 (36.8)	676 (44.0)	3,805 (38.6)
Employment Status				
Active full-time/part-time	462 (44.8)	8,187 (46.0)	784 (51.1)	4,871 (49.5)
Retiree	240 (23.3)	2,853 (16.0)	300 (19.6)	1,680 (17.1)
Other/unknown	329 (31.9)	6,763 (38.0)	451 (29.4)	3,298 (33.5)
Region				
Northeast	206 (20.0)	2,777 (15.6)	262 (17.1)	1596 (16.2)
North-central	194 (18.8)	3,700 (20.8)	289 (18.8)	2019 (20.5)
South	451 (43.7)	7,745 (43.5)	690 (45.0)	4143 (42.1)
West	156 (15.1)	3,060 (17.2)	257 (16.7)	1891 (19.2)
Unknown	24 (2.3)	521 (2.9)	37 (2.4)	200 (2.0)
Industry				

	New users of		Switchers to	
	Tofacitinib (n = 1,031)	**bDMARDs (n = 17,803)**	**Tofacitinib (n = 1,535)**	**bDMARDs (n = 9,849)**
Manufacturing	232 (22.5)	3,726 (20.9)	351 (22.9)	2,114 (21.5)
Transportation, communications, utilities	153 (14.8)	1,929 (10.8)	191 (12.4)	1,152 (11.7)
Retail trade	25 (2.4)	528 (3.0)	49 (3.2)	328 (3.3)
Finance, insurance, real estate	73 (7.1)	18,8324 (7.4)	132 (8.6)	744 (7.6)
Services	136 (13.2)	2,865 (16.1)	264 (17.2)	1,659 (16.8)
Other/unknown	412 (40.0)	7,431 (41.7)	548 (35.7)	3,852 (39.1)
Clinical status and comorbidities				
Deyo comorbidity score = 0	609 (59.1)	11,879 (66.7)	1,012 (65.9)	6,717 (68.2)
Pleural effusion	27 (2.6)	319 (1.8)	32 (2.1)	174 (1.8)
Number of days with ambulatory visits – mean (SD)	21.8 (16.6)	19.9 (15.4)	23.1 (17)	22.6 (15.8)
Number of days in hospital – mean (SD)	0.9 (3.9)	0.5 (2.6)	0.7 (2.8)	0.5 (2.7)
Use of medications in the previous year				
Azathioprine	31 (3.0)	318 (1.8)	38 (2.5)	209 (2.1)

	New users of		Switchers to	
	Tofacitinib (n = 1,031)	**bDMARDs (n = 17,803)**	**Tofacitinib (n = 1,535)**	**bDMARDs (n = 9,849)**
Hydroxychloroquine	257 (24.9)	4,751 (26.7)	313 (20.4)	2,181 (22.1)
Leflunomide	215 (20.9)	2,349 (13.2)	274 (17.9)	1,633 (16.6)
Methotrexate	549 (53.2)	10,566 (59.3)	796 (51.9)	5,476 (55.6)
Minocycline	16 (1.6)	205 (1.2)	32 (2.1)	108 (1.1)
Sulfasalazine	115 (11.2)	1814 (10.2)	108 (7.0)	797 (8.1)
Prednisone	651 (63.1)	9,871 (55.4)	956 (62.3)	5,969 (60.6)
Non-steroidal anti-inflammatory drugs	164 (15.9)	2,614 (14.7)	232 (15.1)	1,543 (15.7)
More than one different bDMARD or tofacitinib	–	–	191 (12.4)	656 (6.7)
Adherent to earlier medication therapy[‡]				
Oral therapy				
Adherent	519 (50.3)	7,627 (42.8)	760 (49.5)	4,680 (47.5)
Non-adherent	411 (39.9)	6,499 (36.5)	659 (42.9)	4,115 (41.8)
Unavailable	101 (9.8)	3,677 (20.7)	116 (7.6)	1,054 (10.7)

	New users of		Switchers to	
	Tofacitinib (n = 1,031)	**bDMARDs (n = 17,803)**	**Tofacitinib (n = 1,535)**	**bDMARDs (n = 9,849)**
Injectable therapy				
Adherent	86 (8.3)	915 (5.1)	576 (37.5)	3,514 (35.7)
Non-adherent	56 (5.4)	1,288 (7.2)	307 (20.0)	1,804 (18.3)
Unavailable	889 (86.2)	15,600 (87.6)	652 (42.5)	4,531 (46.0)

* Data are presented as number of patients (percentage) treated with this medication, unless otherwise specified. Diagnosis of ascites and use of aurothiomalate, cyclosporine, and penicillamine in the previous year are not shown due to the rarity of this use; i.e., there were less than 25 users in each cohort.

† Duration of available follow-up was measured from cohort entry until the end of enrollment, defined as a gap of 90 days or longer, or the end of the study period (December 31, 2016).

‡ Users were defined as adherent to earlier medication therapy if the mean medication possession ratio for oral or injectable antihypertensive, antidiabetic, and antirheumatic medication prescribed in the two years before cohort entry was 80% or greater. Adherence “unknown” was assigned if the patients did not obtain any of the medications or had only one dispensation. See the online supplementary materials for details.